BFM
RCUS icon

Boothbay Fund Management’s Arcus Biosciences RCUS Stock Holding History

Boothbay Fund Management’s Portfolio RCUS Stock Details RCUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.76M Buy
+154,264
New +$3.81M 0.06% 374
2025
Q3 		– Sell
-99,457
Closed -$810K – 2108
2025
Q2 		$810K Buy
99,457
+50,000
+101% +$427K 0.02% 760
2025
Q1 		$388K Sell
49,457
-65,088
-57% -$755K 0.01% 958
2024
Q4 		$1.71M Sell
114,545
-112,026
-49% -$1.83M 0.04% 484
2024
Q3 		$3.46M Buy
226,571
+182,042
+409% +$2.87M 0.08% 345
2024
Q2 		$678K Buy
+44,529
New +$719K 0.02% 887
2023
Q4 		– Sell
-55,772
Closed -$891K – 1921
2023
Q3 		$1M Sell
55,772
-138,408
-71% -$2.78M 0.02% 765
2023
Q2 		$3.94M Sell
194,180
-24,201
-11% -$461K 0.09% 301
2023
Q1 		$3.98M Buy
218,381
+190,537
+684% +$3.64M 0.08% 344
2022
Q4 		$576K Buy
+27,844
New +$766K 0.01% 1116
2022
Q2 		– Sell
-30,800
Closed -$972K – 2598
2022
Q1 		$972K Buy
+30,800
New +$1.03M 0.02% 924

Other funds holding RCUS

GS
Gilead Sciences Foster City, California $1.65B AUM 166.99% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Boothbay Fund Management's RCUS Position: Q2 2026 in Review

Boothbay Fund Management opened a new position in Arcus Biosciences (RCUS) in Q2 2026: 154,264 shares worth $4.76M. The stake represents 0.06% of the portfolio and ranks #374 among its holdings. This is a return to the name: Boothbay Fund Management previously reported a position in RCUS as recently as Q2 2025.

Boothbay Fund Management first reported a position in RCUS in Q1 2022 and has held it in 11 quarters since. 231 funds tracked by Wall St. Rank hold RCUS as of Q2 2026.

  • Boothbay Fund Management held 154,264 shares of Arcus Biosciences worth $4.76M as of Q2 2026.
  • Arcus Biosciences was a new Boothbay Fund Management position in Q2 2026.
  • Arcus Biosciences made up 0.06% of Boothbay Fund Management's portfolio in Q2 2026, its #374 holding.
  • Boothbay Fund Management first reported a position in Arcus Biosciences in Q1 2022 and has held it in 11 quarters since.
  • 231 funds tracked by Wall St. Rank held Arcus Biosciences as of Q2 2026.

Based on Boothbay Fund Management's 13F filing for Q2 2026, filed 14 Aug 2026.